14/05/2019 15:23:25

GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress

ATLANTA, May 14, 2019 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVXD), a biotechnology company developing human vaccines, today announced its financial results for the three months ended March 31, 2019 and provided an update on its corporate development progress.

David A. Dodd, GeoVax’s President and CEO, commented, “To date during 2019, we continue to make progress in several of our key focus areas despite the limited capital resources which have constrained our activities. Nonetheless, through the efforts of our dedicated staff here are a few recent examples of our collaboration and funding achievements:

Cancer Immunotherapy – We continued our work with Leidos, Inc. under our collaboration to evaluate delivery of Leidos’ novel PD-1 checkpoint inhibitors with our MVA-VLP platform for multiple immunotherapeutic vaccine candidates;

Malaria Vaccine – We expanded our relationship with Leidos to include development of malaria vaccine candidates supported under a contract to Leidos from the United States Agency for International Development (USAID) Malaria Vaccine Development Program (MVDP);

Lassa Fever Vaccine – We continued our progress in this program with support from a U.S. Department of Defense grant to advance the vaccine through nonhuman primate testing and manufacturing process development in preparation for human clinical trials;

Zika, Lassa, Ebola and Marburg Vaccines, Unique Delivery – We began a collaboration with Enesi Pharma related to their novel, needle-free ImplaVax® device. We expect this program to result in development of thermostable solid-dose needle-free vaccines for a variety of infectious diseases;

HIV Preventive Vaccine – We are progressing to the next stage of human clinical testing with support from the HIV Vaccine Trials Network (HVTN) and funding from the National Institute of Allergy and Infectious Diseases (NIAID). We expect HVTN to begin the next study (HVTN 132) within the next several months;

HIV “Cure” Program - Our collaboration with American Gene Technologies International, Inc. (AGT), for use of our vaccine in combination with AGT’s gene therapy for development of a functional cure for HIV, is on track to enter human clinical trials sponsored by AGT during the second half of 2019.  We also are continuing discussions with other consortiums for the use of our vaccine in similar efforts toward developing a cure for HIV infection;

Joint Development Collaborations – We continue to engage in promising discussions related to various joint development collaborations that may result in full product development agreements, as well as strategic investments by potential partners."

Mr. Dodd continued, “We are intent upon entering clinical development status for one or more of our development programs within the next 12-18 months, expanding beyond and building upon, our HIV clinical trials. To that end, our goals include restructuring our equity capital, including new capital investment, with our shares trading on a more acceptable stock exchange (e.g. Nasdaq) that will support and sustain the level of operational investment necessary to proceed into human clinical trials. On May 2, 2019, we took one step toward realizing this goal by effecting a one-for-five hundred (1:500) reverse split of our common stock, following shareholder approval of the reverse split on April 15. While this may be an unpopular action among some of our shareholders, it is necessary to ensure our access to the capital critical to continue with and, more importantly, to accelerate our promising product development. There is still additional work needed to be done before we can realistically achieve a Nasdaq listing and a larger capital raise, but that remains our goal and we are confident we will be successful – the promise of our science is too good for us to fail.”

Financial Review

GeoVax reported a net loss for the three months ended March 31, 2019 of $701,454, or $1.43 per share, based on 491,707 weighted-average shares outstanding. For the three months ended March 31, 2018, the Company reported a loss of $621,813, or $2.50 per share, based on 248,340 weighted-average shares outstanding.  The Company reported revenues of $364,232 for the three months ended March 31, 2019, primarily related to grants from the NIH. This compares to $221,299 of grant revenues reported for the same period in 2018. Research and development (R&D) expenses were $555,718 for the three months ended March 31, 2019, compared with $486,994 for the comparable period in 2018. General and administrative (G&A) expenses were $510,064 and $357,228 for the three months ended March 31, 2019 and 2018, respectively. Cash balances were $175,985 at March 31, 2019, as compared to $259,701 at December 31, 2018.

Summarized financial information is attached. Further information concerning the Company’s financial position and results of operations are included in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within (in vivo) the person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.

GeoVax’s current development programs are focused on preventive vaccines against HIV, Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines against chronic Hepatitis B infections and cancers. The Company has designed the leading preventative HIV vaccine candidate to fight against the subtype of HIV prevalent in the larger commercial markets of the Americas, Western Europe, Japan, and Australia; this program is currently undergoing human clinical trials managed by the HIV Vaccine Trials Network (HVTN) with the support of the National Institutes of Health (NIH).  GeoVax’s HIV vaccine is also part of collaborative efforts to develop an immunotherapy as a functional cure for HIV.  For more information, visit www.geovax.com.

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax’s vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements and does not intend to do so. More information about these factors is contained in GeoVax's filings with the SEC including those set forth at "Risk Factors" in GeoVax's Form 10-K.

Contact:

GeoVax Labs, Inc.

investor@geovax.com

678-384-7220

FINANCIAL TABLES FOLLOW

 
 

GEOVAX LABS, INC.

Condensed Consolidated Statements of Operations Information

(amounts in thousands, except share and per share data)

 

    
   Three Months Ended
   March 31,
    2019  2018 
Grant and collaboration revenues $364 $221 
         
Operating expenses:       
 Research and development  556  487 
 General and administrative  510  357 
    1,066  844 
 Loss from operations  (702) (623)
 Other income (expense), net  1  1 
         
Net loss $(701)$(622)
         
Net loss per common share $(1.43)$(2.50)
        
Weighted average common shares outstanding  491,707  248,340 
        
        

Condensed Consolidated Balance Sheet Information

(amounts in thousands)

  March 31,

2019

Dec. 31,

2018

Assets:       
 Cash and cash equivalents $176 $260 
 Other current assets  272  360 
 Total current assets  448  620 
         
 Property, net  14  11 
 Other assets  11  11 
 Total assets $473 $642 
         
Liabilities and stockholders’ equity (deficiency)       
 Current liabilities $1,645 $1,624 
 Note payable, net of current portion  35  40 
 Stockholders’ equity (deficiency)  (1,207) (1,022)
 Total liabilities and stockholders’ equity (deficiency) $473 $642 
         
 Common Shares Outstanding  556,489  437,807 

GOVX new logo.png

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 May
OMXC25
Et stort flertal af klimaforskerne mener klimaændringerne er menneskeskabte. Dvs. de uddannede perso..
28
15 May
DANSKE
Meget interessant refleksion skrevet af Maui. Det kan vores medier godt lære lidt af. Det der kommer..
25
15 May
PNDORA
I gaar aftes sad jeg og kiggede lidt naermere paa guidance fra Pandora for FY2019, som de meldte ud ..
22
14 May
E:THIN
Så sidder jeg her og glor på mit depot. Thinfilm falder ekstra meget i øjnene med afkast på minus 96..
20
17 May
VELO
Hej Alle,   Har siddet og kigget på regnskabet, for at finde ud af hvordan 2019 ender. Umiddelbart e..
18
18 May
VWS
Ditlev.. Havde store ambitioner, og store armbevægelser .. Ikke alt gik godt.. Men finanskrisen kan..
17
18 May
OMXC25
Når man begynder at bruge børn som Greta Thunberg for at fremhæve et budskab ringer advarselsklokker..
17
15 May
DANSKE
Apropos skribent 6212.. Og Danske Bank..Ja så må man lade vedkommende at han/hun fik ret. Han anbefa..
16
14 May
DANSKE
Sjovt at der ikke er nogen kritik af SKATs manglende kontrolindsats i forbindelse med momssvindlen, ..
16
18 May
ZEAL
Nedenfor er det samlet udskift af Q1 telefonkonferencen for Zealand Pharma.    Jeg har først trukket..
15

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
FDA and Infant Bacterial Therapeutics agree on the design of Phase III study
2
New Report Shows CRC Screening Rates Increased When a Medically Underserved Population is Offered Epi proColon® Blood Test
3
PRF: Consolidated Unaudited Interim Report of AS PRFoods for 3rd quarter and 9 months of 2018/2019 financial year
4
Eimskip: Letter from Gylfi Sigfússon´s attorney concerning District Prosecutor‘s investigation
5
Trilogy International Partners Inc. Announces New Zealand CEO Transition

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
20 May 2019 12:15:56
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190514.2 - EUROWEB3 - 2019-05-20 13:15:56 - 2019-05-20 12:15:56 - 1000 - Website: OKAY